Volume 31, Issue 10 pp. 1065-1073
RESEARCH REPORT

Antibodies to human leukocyte antigens and their association with blood product exposures in pediatric patients undergoing cardiac transplantation

Susana Cruz-Beltran

Susana Cruz-Beltran

Department of Anesthesiology, University of Florida, Gainesville, Florida, USA

Search for more papers by this author
Andrea Lane

Andrea Lane

Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

Search for more papers by this author
Shivani Seth

Shivani Seth

Robert Larner College of Medicine, University of Vermont, Burlington, Vermont, USA

Search for more papers by this author
Kati Miller

Kati Miller

Department of Clinical Research, Children’s Healthcare of Atlanta, Atlanta, Georgia, USA

Search for more papers by this author
Reneé H. Moore

Reneé H. Moore

Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

Search for more papers by this author
Harold C. Sullivan

Harold C. Sullivan

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Search for more papers by this author
Ross M. Fasano

Ross M. Fasano

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Search for more papers by this author
Nina A. Guzzetta

Corresponding Author

Nina A. Guzzetta

Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA

Division of Pediatric Anesthesiology, Children’s Healthcare of Atlanta, Atlanta, Georgia, USA

Correspondence

Nina A. Guzzetta, Department of Anesthesiology, Emory University School of Medicine, Children’s Healthcare of Atlanta, 1405 Clifton Road, NE, Atlanta, Georgia 30322, USA.

Email: [email protected]

Search for more papers by this author
First published: 07 August 2021
Citations: 4

Abstract

Background and Aims

Previous blood product exposures may result in the development of antibodies to human leukocyte antigens (HLA). Pediatric heart transplant recipients who have these antibodies experience increased morbidity and mortality after transplantation. In this study, our aims were to confirm the association of previous allogeneic blood product exposures with the formation of anti-HLA antibodies, determine which blood components pose the greatest risk of developing antibodies, and assess differences in outcomes after transplantation between patients who had anti-HLA antibodies and those who did not.

Methods

This retrospective investigation included all children who underwent cardiac transplantation at Children's Healthcare of Atlanta from January 1, 2015 through December 31, 2018. Chart reviews were performed to collect pertinent data. Anti-HLA antibodies were detected by single antigen bead testing. Antibody burden was tabulated using the calculated panel reactive antibody (cPRA) score immediately prior to transplantation. Statistical analyses were conducted to examine differences based on HLA antibody status and identify associations with outcomes of interest.

Results

Our results show a significant association between pretransplant blood product exposures and HLA antibody status. Children with a pretransplant blood product exposure had 7.98 times the odds of developing an anti-HLA antibody compared to those without a pretransplant blood product exposure (p = .01). We also found a significant association between a previous red blood cell (RBC) exposure and HLA antibody status (p = .01) which was not found for other blood component exposures. Patients who were HLA antibody positive were more likely to develop a donor-specific antibody (DSA) after transplantation (p = .04).

Conclusions

Exposure to previous allogeneic blood products affects the development of anti-HLA antibodies in children presenting for heart transplantation. Previous RBC exposures resulted in HLA antibody positivity more than other blood component exposures. Importantly, the presence of HLA antibodies was associated with the development of DSAs post-transplantation. Developing transfusion strategies to reduce allogeneic blood product exposures in children who may need future cardiac transplantation should be a high priority.

CONFLICT OF INTEREST

The authors report no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.